Xeris Pharmaceuticals, Inc

(NASDAQ:XERS)

Latest On Xeris Pharmaceuticals, Inc (XERS):

Date/Time Type Description Signal Details
2023-05-09 20:02 ESTNewsXeris Pharmaceuticals GAAP EPS of -$0.12 beats by $0.05, revenue of $33.2M beats by $2.43MN/A
2023-05-09 20:01 ESTNewsXeris Biopharma Holdings, Inc. (XERS) Q1 2023 Earnings Call TranscriptN/A
2023-05-08 17:08 ESTNewsXeris Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-04-18 16:47 ESTNewsXeris stock trades higher on US patent covering XeriSol formulationsN/A
2023-03-30 18:12 ESTNewsRegeneron in research agreement with Xeris BiopharmaN/A
2023-03-28 13:55 ESTNewsXeris Biopharma: Picks And Shovels Play Has Long-Term Growth PotentialN/A
2023-03-10 00:33 ESTNewsXeris Pharmaceuticals GAAP EPS of -$0.10 beats by $0.06, revenue of $33.14M beats by $2.1MN/A
2023-03-08 17:55 ESTNewsXeris Pharmaceuticals GAAP EPS of -$0.10 beats by $0.06, revenue of $32.54M beats by $1.5MN/A
2023-03-08 17:55 ESTNewsXeris Biopharma Holdings, Inc. (XERS) Q4 2022 Earnings Call TranscriptN/A
2023-03-08 17:55 ESTNewsXeris stock falls ~10% despite revenue growth, narrowed loss in Q4N/A
2023-02-20 02:04 ESTNewsXeris Biopharma: Assessing The Growth And Valuation DisparityN/A
2023-01-30 20:17 ESTNewsXeris stock rises on FDA orphan drug status for hormone disorder therapy RecorlevN/A
2023-01-05 15:43 ESTNewsXeris Biopharma stock rises on 2022 outlook updateN/A
2022-11-23 21:35 ESTNewsXeris, Horizon team up to develop ready-to-use form of thyroid eye disease drugN/A
2022-11-12 13:36 ESTNewsXeris Biopharma: Q3 Earnings Reveals Strong Growth And Path To BreakevenN/A
2022-11-09 14:50 ESTNewsXeris Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01, revenue of $29.6M beats by $0.48MN/A
2022-11-09 14:49 ESTNewsXeris Biopharma Holdings, Inc. (XERS) Q3 2022 Earnings Call TranscriptN/A
2022-11-08 21:25 ESTNewsXeris Pharmaceuticals Q3 2022 Earnings PreviewN/A
2022-10-20 07:51 ESTNewsXeris injectable therapy for hypothyroidism matches oral formulation in phase 1 trialN/A
2022-08-11 01:42 ESTNewsXeris Pharmaceuticals net loss narrows as Q2 results beat on bottom lineN/A
2022-08-11 01:42 ESTNewsXeris Biopharma Holdings, Inc. (XERS) CEO Paul Edick on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-11 01:42 ESTNewsXeris Biopharma: Marching Towards An Inflection PointN/A
2022-08-10 07:40 ESTNewsXeris Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-08-10 07:39 ESTNewsXeris Pharmaceuticals GAAP EPS of -$0.19 beats by $0.04, revenue of $25.31M misses by $0.22MN/A
2022-08-01 17:50 ESTNewsXeris amends commercial terms for hypoglycemia therapy as partner inks buyout dealN/A
2022-05-21 23:34 ESTNewsXeris Biopharma: Q1 Earnings Reveal Path To BreakevenN/A
2022-05-16 22:53 ESTNewsXeris Biopharma spikes as CEO buys company sharesN/A
2022-05-11 12:48 ESTNewsXeris Pharmaceuticals GAAP EPS of -$0.25 in-line, net product revenue of $21.91M misses by $1.48MN/A
2022-05-11 12:48 ESTNewsXeris stock falls 8% after missing Q1 revenue estimatesN/A
2022-05-11 12:48 ESTNewsXeris Biopharma Holdings, Inc. (XERS) CEO Paul Edick on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-10 17:11 ESTNewsXeris Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-03-11 00:11 ESTNewsXeris Biopharma Holdings, Inc. (XERS) CEO Paul Edick on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-10 07:28 ESTNewsXeris Pharmaceuticals GAAP EPS of -$0.42 misses by $0.14, net product revenue of $21.36MN/A
2022-03-10 07:28 ESTNewsXeris Biopharma receives $150M in senior secured term loan facility with Hayfin CapitalN/A
2022-03-09 15:02 ESTNewsXeris Pharmaceuticals Q4 2021 Earnings PreviewN/A
2022-02-22 12:56 ESTNewsXeris Continues To Execute And Build Long-Term Value PotentialN/A
2022-02-18 04:00 ESTNewsXeris Biopharma (XERS) Investor Presentation - SlideshowN/A
2022-01-31 09:10 ESTNewsXeris Biopharma launches Recorlev for Cushing’s SyndromeN/A
2022-01-29 08:39 ESTNewsXeris Biopharma files for $250M mixed shelf offering; shares down 3% postmarketN/A
2022-01-18 12:54 ESTNewsXeris Biopharma reaffirms FY'21 guidanceN/A
2022-01-13 23:18 ESTNewsPANTHERx Rare to distribute Xeris Biopharma's Recorlev for Cushing's syndromeN/A
2022-01-03 11:50 ESTNewsXeris Biopharma to raise $30M in private placement offeringN/A
2021-12-30 20:47 ESTNewsXeris wins FDA approval of levoketoconazole for Cushing syndrome conditionN/A
2021-12-19 22:17 ESTNewsXeris Biopharma: Market Is Snubbing The Strongbridge AcquisitionN/A
2021-12-16 16:48 ESTNewsXeris Bio's Ogluo now available in U.K. for treatment of hypoglycaemiaN/A
2021-11-10 18:38 ESTNewsXeris Pharmaceuticals revenue in-lineN/A
2021-11-10 18:37 ESTNewsXeris Biopharma Holdings, Inc. (XERS) CEO Paul Edick on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-09 19:57 ESTNewsXeris Pharmaceuticals Q3 Earnings PreviewN/A
2021-10-30 02:45 ESTNewsXeris gains 6% following H.C. Wainwright buy initiation; sees 122% returnN/A
2021-10-26 04:41 ESTNewsXeris Biopharma enters partnership with Merck for platform technologyN/A

About Xeris Pharmaceuticals, Inc (XERS):

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.

XERS Quotes by TradingView

See Advanced Chart

General

  • Name Xeris Pharmaceuticals, Inc
  • Symbol XERS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 180
  • Fiscal Year EndDecember
  • IPO Date2018-06-21
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.xerispharma.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 9.75
  • Price/Book (Most Recent Quarter) 6.69
  • Enterprise Value Revenue 8.88
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.22
  • Next Year EPS Estimate -$0.64
  • Next Quarter EPS Estimate -$0.46
  • Operating Margin -401%
  • Return on Assets -38%
  • Return on Equity -378%
  • Revenue 20.44 million
  • Earnings Per Share -$4.11
  • Revenue Per Share $0.48
  • Gross Profit 11.21 million
  • Quarterly Earnings Growth 284.8%
View More

Highlights

  • Market Capitalization 285.17 million
  • EBITDA -94216000
  • PE Ratio -7.03
  • Analyst Target Price $11.25
  • Book Value Per Share $0.57
View More

Share Statistics

  • Shares Outstanding 66.32 million
  • Shares Float 55.38 million
  • % Held by Insiders 238%
  • % Held by Institutions 54.31%
  • Shares Short 8.51 million
  • Shares Short Prior Month 5.89 million
  • Short Ratio 2.98
  • Short % of Float 18%
  • Short % of Shares Outstanding 17%
View More

Technicals

  • Beta 1.97
  • 52 Week High $7.94
  • 52 Week Low $1.45
  • 50 Day Moving Average 5.64
  • 200 Day Moving Average 5.29
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Xeris Pharmaceuticals, Inc (XERS) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Xeris Pharmaceuticals, Inc (XERS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-09$7.09 million-$0.41-$0.39-5.13%
2020-09-302020-11-09$9.45 million-$0.35-$0.5130.93%
2020-06-302020-08-10$N/A-$0.63-$0.7414.48%
2020-03-312020-05-07$N/A-$0.89-$0.911.84%
2019-12-312020-03-11$1.83 million-$1.23-$1.13-9.17%
2019-09-302019-11-07$323000-$1.22-$1.18-3.83%
2019-06-302019-08-06$320000-$1.28-$0.93-38.38%
2019-03-312019-05-09$248000-$1.07-$0.71-51.77%
2018-12-312019-03-06$801000-$0.98-$0.86-13.95%
2018-09-302018-11-07$582000-$0.71-$1.1638.79%
2018-06-302018-08-13$819000-$0.93-$1.0713.27%

Xeris Pharmaceuticals, Inc (XERS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Xeris Pharmaceuticals, Inc (XERS) Chart:

Xeris Pharmaceuticals, Inc (XERS) News:

Below you will find a list of latest news for Xeris Pharmaceuticals, Inc (XERS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Xeris Pharmaceuticals, Inc (XERS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-04-172.53.3CALL0 397280.28TRUE00
2025-04-1750.7CALL112 196366.98TRUE00
2025-04-177.50.05CALL0 157878.83FALSE00
2025-04-172.50.05PUT0 95250.85FALSE00
2025-04-1750.06PUT0 45957.29FALSE00
2025-04-177.51.72PUT0 2108.67TRUE00
2025-05-162.53.25CALL0 6211.93TRUE00
2025-05-1650.85CALL40 2463.93TRUE0.850
2025-05-167.50.1CALL8 15369.43FALSE0.10
2025-05-16100.05CALL0 25122.94FALSE00
2025-05-162.50PUT0 0265.42FALSE00
2025-05-1650.15PUT0 2579.63FALSE00
2025-05-167.51.95PUT0 3271.52TRUE00
2025-05-16100PUT0 0137.15TRUE00
2025-07-182.53.25CALL0 39089.81TRUE00
2025-07-1851.02CALL3 144356.21TRUE0.020.02
2025-07-187.50.23CALL365 53959.97FALSE-0.02-0.08
2025-07-18100.05CALL40 5662.09FALSE0.050
2025-07-182.50.05PUT0 2683.03FALSE00
2025-07-1850.4PUT0 11151.19FALSE00
2025-07-187.52.17PUT1 069.37TRUE2.170
2025-07-18100PUT0 081.15TRUE00
2025-10-172.53.2CALL2 36875.14TRUE-0.1-0.03
2025-10-1751.25CALL78 136955.68TRUE-0.3-0.19
2025-10-177.50.47CALL37 57760.17FALSE-0.03-0.06
2025-10-17100.2CALL0 261.27FALSE00
2025-10-172.50.1PUT0 141135.08FALSE00
2025-10-1750.6PUT0 15165.26FALSE00
2025-10-177.50PUT0 064.78TRUE00
2025-10-17100PUT0 074.69TRUE00

Latest XERS Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST200$1.615
Jun 13, 2022 7:59 PM EST100$1.615
Jun 13, 2022 7:59 PM EST100$1.615
Jun 13, 2022 7:59 PM EST100$1.615
Jun 13, 2022 7:59 PM EST100$1.615

Xeris Pharmaceuticals, Inc (XERS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630220000045/0001346302-20-000045-index.htm
2019-02-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1346302/000000000019001649/0000000000-19-001649-index.htm
2019-08-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1346302/000000000019012227/0000000000-19-012227-index.htm
2018-11-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1346302/000031506618002493/0000315066-18-002493-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1346302/000031506619001407/0000315066-19-001407-index.htm
2020-01-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1346302/000031506620000022/0000315066-20-000022-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1346302/000083423720008166/0000834237-20-008166-index.htm
2018-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924318018502/0000899243-18-018502-index.htm
2018-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924318018505/0000899243-18-018505-index.htm
2018-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924318018506/0000899243-18-018506-index.htm
2019-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319000160/0000899243-19-000160-index.htm
2019-01-093Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319000873/0000899243-19-000873-index.htm
2019-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319001206/0000899243-19-001206-index.htm
2019-02-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319002322/0000899243-19-002322-index.htm
2019-02-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319002323/0000899243-19-002323-index.htm
2019-02-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319002326/0000899243-19-002326-index.htm
2019-02-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319002330/0000899243-19-002330-index.htm
2019-02-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319002331/0000899243-19-002331-index.htm
2019-02-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319002332/0000899243-19-002332-index.htm
2019-02-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319004561/0000899243-19-004561-index.htm
2019-02-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319004590/0000899243-19-004590-index.htm
2019-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319004728/0000899243-19-004728-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319005457/0000899243-19-005457-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319005458/0000899243-19-005458-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319005460/0000899243-19-005460-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319005461/0000899243-19-005461-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319005463/0000899243-19-005463-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319005464/0000899243-19-005464-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319007350/0000899243-19-007350-index.htm
2019-04-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319010607/0000899243-19-010607-index.htm
2019-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319019198/0000899243-19-019198-index.htm
2019-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319019200/0000899243-19-019200-index.htm
2019-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319019201/0000899243-19-019201-index.htm
2019-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319019202/0000899243-19-019202-index.htm
2019-09-124/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319023467/0000899243-19-023467-index.htm
2019-10-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319024729/0000899243-19-024729-index.htm
2019-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319024732/0000899243-19-024732-index.htm
2019-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319025613/0000899243-19-025613-index.htm
2019-11-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319027693/0000899243-19-027693-index.htm
2019-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924319028235/0000899243-19-028235-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320000614/0000899243-20-000614-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320000615/0000899243-20-000615-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320000617/0000899243-20-000617-index.htm
2020-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320001167/0000899243-20-001167-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320002835/0000899243-20-002835-index.htm
2020-02-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320004900/0000899243-20-004900-index.htm
2020-02-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320004907/0000899243-20-004907-index.htm
2020-02-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320004912/0000899243-20-004912-index.htm
2020-02-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320004913/0000899243-20-004913-index.htm
2020-02-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320004914/0000899243-20-004914-index.htm
2020-03-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320006508/0000899243-20-006508-index.htm
2020-03-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320006512/0000899243-20-006512-index.htm
2020-03-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320006514/0000899243-20-006514-index.htm
2020-03-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320006515/0000899243-20-006515-index.htm
2020-03-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320006521/0000899243-20-006521-index.htm
2020-03-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320006522/0000899243-20-006522-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320008434/0000899243-20-008434-index.htm
2020-05-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320012590/0000899243-20-012590-index.htm
2020-05-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320012625/0000899243-20-012625-index.htm
2020-05-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320013088/0000899243-20-013088-index.htm
2020-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320015323/0000899243-20-015323-index.htm
2020-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320015326/0000899243-20-015326-index.htm
2020-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320015328/0000899243-20-015328-index.htm
2020-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320015329/0000899243-20-015329-index.htm
2020-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320015330/0000899243-20-015330-index.htm
2020-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320015333/0000899243-20-015333-index.htm
2020-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320019177/0000899243-20-019177-index.htm
2020-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320019178/0000899243-20-019178-index.htm
2020-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320019179/0000899243-20-019179-index.htm
2020-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320019180/0000899243-20-019180-index.htm
2020-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320022554/0000899243-20-022554-index.htm
2020-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320022572/0000899243-20-022572-index.htm
2020-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320022573/0000899243-20-022573-index.htm
2020-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320022591/0000899243-20-022591-index.htm
2020-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000089924320023069/0000899243-20-023069-index.htm
2018-06-283/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000090866218000174/0000908662-18-000174-index.htm
2018-06-284/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000090866218000175/0000908662-18-000175-index.htm
2019-01-07DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1346302/000095012319000041/0000950123-19-000041-index.htm
2020-07-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1346302/000101143820000164/0001011438-20-000164-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1346302/000110465920021836/0001104659-20-021836-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1346302/000114036120002569/0001140361-20-002569-index.htm
2020-03-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1346302/000114036120005220/0001140361-20-005220-index.htm
2019-02-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000114420419009310/0001144204-19-009310-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1346302/000117266120000912/0001172661-20-000912-index.htm
2018-06-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000119312518205989/0001193125-18-205989-index.htm
2018-11-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000119312518332798/0001193125-18-332798-index.htm
2019-02-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1346302/000119312519032355/0001193125-19-032355-index.htm
2019-02-11S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1346302/000119312519033935/0001193125-19-033935-index.htm
2019-02-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1346302/000119312519034084/0001193125-19-034084-index.htm
2019-02-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1346302/000119312519034089/0001193125-19-034089-index.htm
2019-02-13S-1MEFRegistration adding securities to prior Form S-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1346302/000119312519038611/0001193125-19-038611-index.htm
2019-02-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000119312519041177/0001193125-19-041177-index.htm
2019-02-14424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1346302/000119312519041206/0001193125-19-041206-index.htm
2019-03-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1346302/000119312519086609/0001193125-19-086609-index.htm
2019-03-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1346302/000119312519086617/0001193125-19-086617-index.htm
2019-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000119312519086630/0001193125-19-086630-index.htm
2019-08-06S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1346302/000119312519214231/0001193125-19-214231-index.htm
2019-08-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1346302/000119312519224505/0001193125-19-224505-index.htm
2020-02-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1346302/000119312520030045/0001193125-20-030045-index.htm
2020-02-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000119312520030046/0001193125-20-030046-index.htm
2020-02-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1346302/000119312520035522/0001193125-20-035522-index.htm
2020-02-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000119312520035547/0001193125-20-035547-index.htm
2020-06-24424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1346302/000119312520177617/0001193125-20-177617-index.htm
2020-06-24424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1346302/000119312520177618/0001193125-20-177618-index.htm
2020-06-26305B2Filing [Trust Indenture Act]https://www.sec.gov/Archives/edgar/data/1346302/000119312520179489/0001193125-20-179489-index.htm
2020-06-26FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1346302/000119312520179824/0001193125-20-179824-index.htm
2020-06-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1346302/000119312520181310/0001193125-20-181310-index.htm
2020-06-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1346302/000119312520181331/0001193125-20-181331-index.htm
2020-09-16DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1346302/000119312520247170/0001193125-20-247170-index.htm
2020-09-25DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1346302/000119312520254565/0001193125-20-254565-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000119380519000089/0001193805-19-000089-index.htm
2019-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000119380519000102/0001193805-19-000102-index.htm
2019-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000119380519000117/0001193805-19-000117-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1346302/000119380519000204/0001193805-19-000204-index.htm
2019-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1346302/000119380519000209/0001193805-19-000209-index.htm
2019-11-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1346302/000119380519001409/0001193805-19-001409-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1346302/000119380520000202/0001193805-20-000202-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630218000008/0001346302-18-000008-index.htm
2018-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630218000011/0001346302-18-000011-index.htm
2018-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1346302/000134630218000016/0001346302-18-000016-index.htm
2018-08-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630218000018/0001346302-18-000018-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630218000021/0001346302-18-000021-index.htm
2018-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1346302/000134630218000025/0001346302-18-000025-index.htm
2019-01-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630219000002/0001346302-19-000002-index.htm
2019-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630219000007/0001346302-19-000007-index.htm
2019-03-0610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1346302/000134630219000009/0001346302-19-000009-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630219000012/0001346302-19-000012-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630219000016/0001346302-19-000016-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1346302/000134630219000019/0001346302-19-000019-index.htm
2019-06-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630219000021/0001346302-19-000021-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630219000028/0001346302-19-000028-index.htm
2019-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1346302/000134630219000029/0001346302-19-000029-index.htm
2019-09-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630219000033/0001346302-19-000033-index.htm
2019-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630219000035/0001346302-19-000035-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630219000037/0001346302-19-000037-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1346302/000134630219000040/0001346302-19-000040-index.htm
2020-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630220000003/0001346302-20-000003-index.htm
2020-03-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1346302/000134630220000007/0001346302-20-000007-index.htm
2020-03-12S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1346302/000134630220000010/0001346302-20-000010-index.htm
2020-04-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630220000012/0001346302-20-000012-index.htm
2020-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1346302/000134630220000019/0001346302-20-000019-index.htm
2020-04-24DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1346302/000134630220000022/0001346302-20-000022-index.htm
2020-04-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630220000024/0001346302-20-000024-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630220000028/0001346302-20-000028-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1346302/000134630220000032/0001346302-20-000032-index.htm
2020-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630220000035/0001346302-20-000035-index.htm
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630220000042/0001346302-20-000042-index.htm
2020-07-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630220000045/0001346302-20-000045-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1346302/000134630220000049/0001346302-20-000049-index.htm
2020-08-18PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1346302/000134630220000054/0001346302-20-000054-index.htm
2020-08-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630220000057/0001346302-20-000057-index.htm
2020-09-02DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1346302/000134630220000061/0001346302-20-000061-index.htm
2020-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000134630220000065/0001346302-20-000065-index.htm
2020-02-21SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1346302/000139834420003916/0001398344-20-003916-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1346302/000162828020012223/0001628280-20-012223-index.htm
2019-02-13EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1346302/999999999519000241/9999999995-19-000241-index.htm
2019-08-21EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1346302/999999999519001941/9999999995-19-001941-index.htm

Xeris Pharmaceuticals, Inc (XERS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Xeris Pharmaceuticals, Inc (XERS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 238%
Institutional Ownership: 5431%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-07-01John Patrick Jr ShannonOfficerBuy1,138.009.7211,061.3610,121.00https://www.sec.gov/Archives/edgar/data/1346302/000089924319019198/0000899243-19-019198-index.htm
2019-12-31John Patrick Jr ShannonOfficerBuy438.005.992,623.6210,559.00https://www.sec.gov/Archives/edgar/data/1346302/000089924320000614/0000899243-20-000614-index.htm
2020-05-13John Patrick Jr ShannonOfficerBuy22,000.003.5577,994.40117,493.00https://www.sec.gov/Archives/edgar/data/1346302/000089924320013088/0000899243-20-013088-index.htm
2019-01-31Paul R EdickOfficerBuy125,000.00125,000.00https://www.sec.gov/Archives/edgar/data/1346302/000089924319002330/0000899243-19-002330-index.htm
2019-03-11Paul R EdickOfficerBuy30,000.009.12273,585.00155,000.00https://www.sec.gov/Archives/edgar/data/1346302/000089924319007350/0000899243-19-007350-index.htm
2019-11-25Paul R EdickOfficerBuy17,935.008.55153,283.27172,935.00https://www.sec.gov/Archives/edgar/data/1346302/000089924319028235/0000899243-19-028235-index.htm
2020-02-14Paul R EdickOfficerBuy20,000.004.1583,000.00183,134.00https://www.sec.gov/Archives/edgar/data/1346302/000089924320004912/0000899243-20-004912-index.htm
2020-02-14John Patrick Jr ShannonOfficerBuy12,048.004.1549,999.2022,607.00https://www.sec.gov/Archives/edgar/data/1346302/000089924320004914/0000899243-20-004914-index.htm
2019-02-19Beth HechtOfficerBuy2,500.0010.0025,000.002,500.00https://www.sec.gov/Archives/edgar/data/1346302/000089924319004561/0000899243-19-004561-index.htm
2020-01-31KENNETH ERLAND JOHNSONOfficerBuy20,000.0026,115.00https://www.sec.gov/Archives/edgar/data/1346302/000089924320006521/0000899243-20-006521-index.htm
2019-02-19Barry M. DeutschOfficerBuy5,000.0010.0050,000.0028,292.00https://www.sec.gov/Archives/edgar/data/1346302/000089924319004590/0000899243-19-004590-index.htm
2019-07-01Barry M. DeutschOfficerBuy1,428.009.7213,880.1629,720.00https://www.sec.gov/Archives/edgar/data/1346302/000089924319019200/0000899243-19-019200-index.htm
2019-02-19Redmile Group, LLC10% Share HolderBuy588,000.0010.005,880,000.003,000,642.00https://www.sec.gov/Archives/edgar/data/1346302/000114420419009310/0001144204-19-009310-index.htm
2019-02-19KENNETH ERLAND JOHNSONOfficerBuy1,000.0010.0010,000.003,245.00https://www.sec.gov/Archives/edgar/data/1346302/000089924319004728/0000899243-19-004728-index.htm
2019-07-01KENNETH ERLAND JOHNSONOfficerBuy174.009.721,691.283,419.00https://www.sec.gov/Archives/edgar/data/1346302/000089924319019201/0000899243-19-019201-index.htm
2020-01-31Paul R EdickOfficerBuy185,000.00368,134.00https://www.sec.gov/Archives/edgar/data/1346302/000089924320006512/0000899243-20-006512-index.htm
2019-12-31KENNETH ERLAND JOHNSONOfficerBuy286.005.991,713.143,705.00https://www.sec.gov/Archives/edgar/data/1346302/000089924320000615/0000899243-20-000615-index.htm
2019-07-01Beth HechtOfficerBuy1,124.009.7210,925.283,928.00https://www.sec.gov/Archives/edgar/data/1346302/000089924319019202/0000899243-19-019202-index.htm
2020-02-14Barry M. DeutschOfficerBuy9,639.004.1540,001.8539,359.00https://www.sec.gov/Archives/edgar/data/1346302/000089924320004900/0000899243-20-004900-index.htm
2020-05-08Paul R EdickOfficerBuy33,000.003.0099,000.00401,134.00https://www.sec.gov/Archives/edgar/data/1346302/000089924320012590/0000899243-20-012590-index.htm
2019-12-31Beth HechtOfficerBuy459.005.992,749.414,083.00https://www.sec.gov/Archives/edgar/data/1346302/000089924320000617/0000899243-20-000617-index.htm
2020-01-13STEVEN PRESTRELSKIChief Scientific OfficerSell10,000.005.5054,992.00421,824.00https://www.sec.gov/Archives/edgar/data/1346302/000089924320001167/0000899243-20-001167-index.htm
2020-01-31STEVEN PRESTRELSKIChief Scientific OfficerBuy15,000.00436,824.00https://www.sec.gov/Archives/edgar/data/1346302/000089924320006522/0000899243-20-006522-index.htm
2019-10-11STEVEN PRESTRELSKIChief Scientific OfficerSell10,000.007.9779,746.00449,324.00https://www.sec.gov/Archives/edgar/data/1346302/000089924319025613/0000899243-19-025613-index.htm
2019-07-11STEVEN PRESTRELSKIChief Scientific OfficerSell38.0012.70482.60459,324.00https://www.sec.gov/Archives/edgar/data/1346302/000089924319025613/0000899243-19-025613-index.htm
2019-07-11STEVEN PRESTRELSKIChief Scientific OfficerSell9,962.0012.04119,912.59459,362.00https://www.sec.gov/Archives/edgar/data/1346302/000089924319025613/0000899243-19-025613-index.htm
2019-01-14STEVEN PRESTRELSKIChief Scientific OfficerSell7,700.0017.20132,459.25469,324.00https://www.sec.gov/Archives/edgar/data/1346302/000089924319025613/0000899243-19-025613-index.htm
2019-04-11STEVEN PRESTRELSKIChief Scientific OfficerSell10,000.009.5695,649.00477,024.00https://www.sec.gov/Archives/edgar/data/1346302/000089924319010607/0000899243-19-010607-index.htm
2019-01-11STEVEN PRESTRELSKIChief Scientific OfficerSell2,300.00487,024.00https://www.sec.gov/Archives/edgar/data/1346302/000089924319001206/0000899243-19-001206-index.htm
2018-12-26STEVEN PRESTRELSKIChief Scientific OfficerSell15,720.0015.82248,737.56489,324.00https://www.sec.gov/Archives/edgar/data/1346302/000089924319000160/0000899243-19-000160-index.htm
2018-12-24STEVEN PRESTRELSKIChief Scientific OfficerBuy15,720.001.1918,706.80505,044.00https://www.sec.gov/Archives/edgar/data/1346302/000089924319000160/0000899243-19-000160-index.htm
2020-01-31Beth HechtOfficerBuy45,000.0053,083.00https://www.sec.gov/Archives/edgar/data/1346302/000089924320006515/0000899243-20-006515-index.htm
2020-03-13Beth HechtOfficerBuy4,000.001.977,880.0057,083.00https://www.sec.gov/Archives/edgar/data/1346302/000089924320008434/0000899243-20-008434-index.htm
2020-02-14KENNETH ERLAND JOHNSONOfficerBuy2,410.004.1510,001.506,115.00https://www.sec.gov/Archives/edgar/data/1346302/000089924320004907/0000899243-20-004907-index.htm
2020-02-14Beth HechtOfficerBuy4,000.004.1516,600.008,083.00https://www.sec.gov/Archives/edgar/data/1346302/000089924320004913/0000899243-20-004913-index.htm
2019-02-11James E Flynn10% Share HolderSell1,351.0015.0020,265.00856,470.00https://www.sec.gov/Archives/edgar/data/1346302/000119380519000209/0001193805-19-000209-index.htm
2019-02-08James E Flynn10% Share HolderSell5,890.0015.1188,985.53857,821.00https://www.sec.gov/Archives/edgar/data/1346302/000119380519000209/0001193805-19-000209-index.htm
2019-02-07James E Flynn10% Share HolderSell9,409.0015.00141,135.00863,711.00https://www.sec.gov/Archives/edgar/data/1346302/000119380519000117/0001193805-19-000117-index.htm
2019-02-06James E Flynn10% Share HolderSell400.0015.006,000.00873,120.00https://www.sec.gov/Archives/edgar/data/1346302/000119380519000117/0001193805-19-000117-index.htm
2019-02-05James E Flynn10% Share HolderSell4,998.0015.0775,307.86873,520.00https://www.sec.gov/Archives/edgar/data/1346302/000119380519000117/0001193805-19-000117-index.htm
2020-01-31John Patrick Jr ShannonOfficerBuy65,000.0087,607.00https://www.sec.gov/Archives/edgar/data/1346302/000089924320006514/0000899243-20-006514-index.htm
2019-01-29James E Flynn10% Share HolderSell6,210.0015.1494,028.09878,518.00https://www.sec.gov/Archives/edgar/data/1346302/000119380519000102/0001193805-19-000102-index.htm
2019-01-28James E Flynn10% Share HolderSell828.0015.0012,420.00884,728.00https://www.sec.gov/Archives/edgar/data/1346302/000119380519000102/0001193805-19-000102-index.htm
2019-01-25James E Flynn10% Share HolderSell76,820.0015.081,158,253.55885,556.00https://www.sec.gov/Archives/edgar/data/1346302/000119380519000089/0001193805-19-000089-index.htm
2020-01-31Barry M. DeutschOfficerBuy50,000.0089,359.00https://www.sec.gov/Archives/edgar/data/1346302/000089924320006508/0000899243-20-006508-index.htm
2020-05-08John Patrick Jr ShannonOfficerBuy7,886.003.2025,219.4395,493.00https://www.sec.gov/Archives/edgar/data/1346302/000089924320012625/0000899243-20-012625-index.htm
2019-01-24James E Flynn10% Share HolderSell5,425.0015.0381,562.71962,376.00https://www.sec.gov/Archives/edgar/data/1346302/000119380519000089/0001193805-19-000089-index.htm
2019-01-23James E Flynn10% Share HolderSell32,199.0016.35526,376.37967,801.00https://www.sec.gov/Archives/edgar/data/1346302/000119380519000089/0001193805-19-000089-index.htm